Core One In Talks With Multiple Companies To Supply Psilocybin
Core One In Talks With Multiple Companies To Supply Psilocybin
By streamlining a psychedelic supply chain and structuring itself as a vertically integrated business, Core One could control the production process of its products and develop an uninterrupted revenue stream. Management regards a robust and reliable supply chain as a key component in establishing its business clientele and capturing a large share of the medicinal and clinical psychedelics' market.Core One Labs Inc. (OTCQB:CLABF) (CSE:COOL)(Frankfurt:LD6), (WKN:A3CSSU) announced that it is in discussions with several pharmaceutical laboratories and research organizations to supply them with active pharmaceutical ingredient psilocybin to meet their psychedelic research needs.
Core One實驗室公司(場外交易代碼：CLABF)(CSE：Cool)(法蘭克福：LD6)，(WKN：A3CSSU)宣佈正在與幾家製藥實驗室和研究機構討論向他們提供活性藥物成分裸蓋菇素以滿足他們迷幻研究的需要。
Scientific interest in psilocybin has grown exponentially in recent years, with many high profile clinical trials showing enormous potential for the psychedelic compound in treating various mental health and neurological disorders, such as anxiety, depression, obsessive-compulsive disorder, various addictions, as well as Alzheimer's and Parkinson's diseases, to name a few. Promising results from many of these trials, though still in early stages and requiring further study, have given rise to rapid growth of a psychedelic industry and the emergence of many public and private entities engaged in research with psychedelics intended for medical use.
近年來，人們對裸蓋菇素的科學興趣呈指數級增長，許多備受矚目的臨床試驗表明，這種迷幻化合物在治療各種精神健康和神經疾病方面具有巨大潛力，例如焦慮、抑鬱、強迫症、各種成癮，以及阿爾茨海默氏症和帕金森氏症等。其中許多試驗取得了令人振奮的結果，儘管仍處於早期階段，需要進一步研究，但已促使迷幻行業迅速增長，並出現了許多公共和私人實體，從事用於醫療用途的迷幻藥物的研究。
The company has the potential to produce its own psychedelic compounds at a Good Manufacturing Practices facility, while, in collaboration with its partners, also manufactures and could supply its quality and cost-effective products to licensed clients in Canada.
該公司有可能在一家良好的製造規範工廠生產自己的迷幻化合物，同時，與其合作夥伴合作，也可以製造並向加拿大的特許客戶提供其高質量和高成本效益的產品。
By streamlining a psychedelic supply chain and structuring itself as a vertically integrated business, Core One could control the production process of its products and develop an uninterrupted revenue stream. Management regards a robust and reliable supply chain as a key component in establishing its business clientele and capturing a large share of the medicinal and clinical psychedelics' market.
通過精簡迷幻供應鏈並將自己構建為垂直整合的業務，Core One可以控制其產品的生產過程，併發展不間斷的收入流。管理層認為，強大而可靠的供應鏈是建立其商業客戶並佔領藥物和臨床迷幻藥市場的很大份額的關鍵組成部分。
"Engaging in talks with multiple companies to supply them with psychedelic compounds demonstrates how far the company has come since initial research and development stages to where it is now. Embarking on the sales aspect of our corporate strategy keeps us ahead of the pack when it comes to being a leading supplier of medicinal psychedelics. We believe that our ability to continue to execute on our goals demonstrates to shareholders and other pharmaceutical companies why Core One is positioned to disrupt the medical industry when it comes to mental health and addiction treatments," stated Joel Shacker, Core One Labs CEO.
他說：“與多家公司進行談判，向他們供應迷幻藥化合物，這表明公司從最初的研發階段到現在已經取得了多大的進步。開始實施公司戰略的銷售方面，使我們在成為一家領先的藥物迷幻藥供應商方面處於領先地位。我們相信，我們有能力繼續執行我們的目標，向股東和其他製藥公司表明，為什麼Core One在心理健康和成癮治療方面處於顛覆醫療行業的地位喬爾·謝克，Core One Labs首席執行官。
Photo: Benzinga edit with photos by geralt, sergeitokmakov on Pixabay
圖片：Benzinga編輯與Geralt，Sergeitokmakov在Pixabay上的照片
Related News
相關新聞
Core One's Awakened Lays The Groundwork For The Large-Scale Production Of Psychedelic Compounds With Synthetic Production Of Psilocin
核心覺醒為人工合成PsiLocin規模化生產迷幻藥奠定基礎
譯文內容由第三人軟體翻譯。
